Study Title: Repurposing a histamine antagonist to benefit patients with 
pulmonary hypertension (REHAB- PH) 
 
National Clinical Trial (NCT) Identified Number: [STUDY_ID_REMOVED] 
 
PI Name: Peter Leary, MD PhD 
 
IRB Approval Dates: 
Initial approval : 8/9/2018 
Current version of the protocol reviewed/approved: 1/20/2023 
Current version of the consent reviewed/approved: 1/20/2023 
Most recent continuing review approval: 4/25/2024 3 4/24/2025  
  
CONFIDENTIAL  
 
 
Clinical Trial Protocol : REHAB -PH 
 
Study Title: Repurposing a histamine antagonist to benefit patients with 
pulmonary hypertension  
(REHAB -PH) 
 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED]  
 
Principal Investigator:  Peter Leary, M.D., Ph.D.  
 
Funded by : National Heart, Lung, and Blood Institute  
 
Version Number:  v.1.8  
 
12 December 2022  
  

  
CONFIDENTIAL Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................  1 
1 PROTOCOL SUMMARY  ..............................................................................................................................  1 
1.1 Synopsis  ...............................................................................................................................................  1 
1.2 Schema  ................................................................................................................................................  4 
1.3 Schedule of Activities (SoA)  ..............................................................................................................  5 
2 INTRODUCTION  ...........................................................................................................................................  6 
2.1 Study Rationale  ...................................................................................................................................  6 
2.2 Background  ..........................................................................................................................................  7 
2.3 Risk/Benefit Assessment  ...................................................................................................................  7 
2.3.1  Potential Risk s .................................................................................................................  7 
2.3.2  Potential Benefits  ............................................................................................................  7 
3 OBJECTIVES AND ENDPOINTS  ...............................................................................................................  8 
4 STUDY DESIGN  ............................................................................................................................................  9 
4.1 Overall Design  .....................................................................................................................................  9 
4.2 Scientific Rationale for Study Design  ...........................................................................................  109 
4.3 Justification for Dose  ........................................................................................................................  10 
4.4 End of Study Definition  .....................................................................................................................  10 
5 STUDY POPULATION  ............................................................................................................................  1110 
5.1 Inclusion Criteria  ...........................................................................................................................  1110 
5.2 Exclusion Criteria  ..............................................................................................................................  11 
5.3 Lifestyle Considerations  ...............................................................................................................  1211 
5.4 Screen Failures  ................................................................................................................................ . 12 
5.5 Strategies for Recruitment and Retention  .....................................................................................  12 
6 STUDY INTERVENTION  ........................................................................................................................  1312 
6.1 Study Intervention(s) Administration  ..........................................................................................  1312 
6.1.1  Study Intervention Description  ................................................................................  1312 
6.1.2  Dosing and Administration  ...........................................................................................  13 
6.2 Preparation/Handling/Storage/Accountability  ...............................................................................  13 
6.2.1  Acquisition and accountability  .....................................................................................  13 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ...........................................  1413 
6.2.3  Product Storage and Stability  ......................................................................................  14 
6.3 Measures to Minimize Bias: Randomization and Blinding  ..........................................................  14 
6.4 Study Intervention Compliance  .......................................................................................................  14 
6.5 Concomitant Therapy  .......................................................................................................................  14 
6.5.1  Rescue Medicine  ...........................................................................................................  15 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ...................................................................................................................  15 
7.1 Participant Discontinuation/Withdrawal from the Study  ..............................................................  15 
7.2 LosS to Follow -Up .............................................................................................................................  16 
8 STUDY ASSESSMENTS AND PROCEDURES  .....................................................................................  16 
8.1 Efficacy AND SAFETY Assessments  ............................................................................................  16 
8.2 Adverse Events and Serious Adverse Events  ..........................................................................  1918 
8.2.1  Definition of Adverse Events (AE)  ...........................................................................  1918 
8.2.2  Definition of Serious Adverse Events (SAE)  .........................................................  1918 
8.2.3  Classification of an Adverse Event  .............................................................................  19 
8.2.4  Time Period and Frequency for Event Assessment and Follo w-Up ......................  20 
  
CONFIDENTIAL 8.2.5  Adverse Event Reporting  .............................................................................................  20 
8.2.6  Reporting Events to Pa rticipants  .................................................................................  21 
8.2.7  Events of Special Interest  ............................................................................................  21 
8.2.8  Reporting of Pregnancy  ................................................................................................  21 
9 STATISTICAL CONSIDERATIONS  ......................................................................................................  2221 
9.1 Statistical Hypotheses  ..................................................................................................................  2221 
9.2 Sample Size Determination  .........................................................................................................  2322 
9.3 Populations for Analyses  .............................................................................................................  2423 
9.4 Statistical Analyses  .......................................................................................................................  2423 
9.4.1  General Approach  .....................................................................................................  2423 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ........................................................  2423 
9.4.3  Analysis o f the Secondary Endpoint(s)  ..................................................................  2524 
9.4.4  Safety Analyses  .........................................................................................................  2524 
9.4.5  demographic and Baseline Descriptive Statistics  .................................................  2625 
9.4.6  DSMB Review of ongoing data  ...............................................................................  2625 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..........................  2726 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ......................................................  2726 
10.1.1  Informed Consent Process  ......................................................................................  2726 
10.1.2  Study Discontinuation and Closure  .........................................................................  2726 
10.1.3  Confidentiality and Privacy  .......................................................................................  2827 
10.1.4  Future Use of Stored Specimens and Data  ...........................................................  2928 
10.1.5  Key Roles and Study Governance  ..........................................................................  2928 
10.1.6  Safety Oversight  ........................................................................................................  2928 
10.1.7  Clinical Monitoring  .....................................................................................................  3029 
10.1.8  Quality Assurance and Quality Control  ..................................................................  3029 
10.1.9  Data Handling and Record Keeping  .......................................................................  3029 
10.1.10  Protocol Deviations  ...................................................................................................  3130 
10.1.11  Publication and Data Sharing Policy  ......................................................................  3130 
10.1.12  Conflict of Interest Policy  ..........................................................................................  3231 
11 REFERENCES  .........................................................................................................................................  3332 
12 APPENDIX 1: EMPHASIS -10 QUESTIONNAIRE  ..............................................................................  3837 
13 APPENDIX 2: FUNCTIONAL CLASS DECISION AID  .......................................................................  3938 
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   1 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonization Good 
Clinical Practice ( ICH GCP) and the following :  
 
" United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12)  
 
National Institutes of Health (NIH )-funded investigators and clinical trial site staff who are 
responsible  for the conduct, management, or  oversight of NIH -funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by the IRB before the changes are 
implemented to the study.  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form . 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS   
Title:  Repurposing a histamine antagonist to benefit patients wit h pulmonary 
hypertension  (REHAB -PH) 
  
Study Description : Pulmonary arterial hypertension (PAH) is one of many condition s that put 
stress and strain on the right side of the heart. This stress and strain can 
cause right heart failure. Although there are medications to treat PAH, 
there are curr ently no medications that act directly on the heart to 
improve right heart function. This is different than left heart failure  where 
one of the cornerstones of treatment is medication targeted at the heart 
to improve left heart function.  
 
Famotidine is a w ell-tolerated, over -the-counter, and inexpensive 
medication. Preliminary results suggest that famotidin e may help the right 
heart to adapt and strengthen when stressed instead of fail; however, 
these results are suggestive and not definitive. A randomized controlled 
trial is required to evaluate the possibility that famotidine can impact right 
heart function.  
 
Objectives:   
 Primary Objective :   
To determine whether famotidine increases six -minute walk 
distance at 24 weeks in men and women with pulmonary arterial 
hypertension.  
 Secondary Objectives:  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sub-study Objectives:  " To determine whether famotidine reduces BNP at 24 weeks  
" To determine whether famotidine improves New York Heart 
Association (NYHA) functional class at 24 weeks  
" To determine whether famotidine improves right ventricular 
morphology  at 24 weeks including improved right ventricular 
diameter  and TAPSE  
" To determine whether famotidine improves health related quality 
of life as estimated by the emPHasis -10 score  
" To determine whether famotidine decreases the need to escalate 
PAH focused care (increased diuretics, escalating doses of 
pulmonary vasodilators, and/or adding an additional pulmonary 
vasodilator) 
" To explore changes in invasive hemodynamics with famotidine  
" To explore changes in gas exchange, maximal oxygen uptake, 
metabolism, and myocardial reserve with famotidine  
 
 
Exercise sub -study:  
" To determine whether famotidine increases maximal oxygen 
uptake in individuals with pulmonary arterial hypertension at 24 
weeks  
" To explore changes in other metrics of the exercise response 
(oxygen uptake, Ve/VCO2 ratio, total achieved wattage) with 
famotidine relative to placebo over 24 weeks.  
" In a <right heart targeted therapy= trial, to explore t he relat ionship 
between markers of the exercise response and other standard 
markers of treatment response including BNP, New York He art 
Association functional class, quality of life, and need  to escalate 
PAH -specific therapy.  
 
Right heart catheterization sub- stud y  
" To determine whether famotidine increases stroke volume index 
at 24 weeks  
" To explore whether famotidine is associated with differences in 
wedge pressure, right atrial pressure, and/or pulmona ry vascular 
resistance at 24 weeks  
" In a <right heart targeted therapy= trial, to explore the relationship 
between markers of the exercise response and other standard 
markers of treatment response including BNP, New York He art 
Association functional class, quality of life, and need  to escalate 
PAH -specific therapy.  
 
 
  
Endpoint s: Primary endpoint: The difference between treatment groups in 6 -minute 
walk distance (6MWD) at 24 weeks.  
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   3 Secondary endpoint: The difference between treatment groups in BNP, 
NYHA functional class, TAPSE, right ventricular basal diameter, emPHasis -
10 score, and number of participants with an escalation of routine clinical 
treatments for PAH for each visit . 
  
Study Population:  Approximately 80 participants, male or female, age 18 to 80 with  
 WHO Group 1 Pulmonary Arterial Hypertension and NYHA  Functional 
Class II, III, or IV at screening.  
  
Phase:  II  
Description of 
Sites /Facilities  Enrolling 
Participants :  All potential subjects for the REHAB -PH Trial will be recruited from the 
University of Washington Pulmonary Vascular Disease Pro gram.   
Description of Study  
Intervention : Famotidine, 20 mg daily, per oral  
  
Study Duration:  60 months   
Participa nt Duration:  Participants will be evaluated and participate over 24 ± 1 weeks.  
  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   5 1.3 SCHEDULE OF ACTIVITIES (SOA)  
  Baseline  Randomization   Phone 
Visit  
Week 4  Week 
12 Week 
24 
Visit #  1  Non-
visit PH 2 3 
Day #  -14 to -1  -1 0 28 ± 7  84 ± 7  168 ± 7  
Inclusion/Exclusion Criteria  X      
Informed Consent  X      
History and physical exam           
  Demographics  X      
  Medical history  X      
  Symptom assessment  X    X X 
  Concomitant medications  X    X X 
  Vital Signs & Weight  X    **X X 
  Physical Examination  X    **X X 
Safety laboratories           
  Laboratory Draw  X     X 
  Comprehensive metabolic panel  X     X 
  Complete blood count  X     X 
  Mass -Spectrometry for H 2 antagonists  X     X 
  Pregnancy test if premenopausal  X     X 
Endpoint assessment           
  6 minute -walk distance (primary)  X                  ** X  X 
  echocardiogram  X     X 
  emPHasis -10 score  X    X X 
  BNP X     X 
  NYHA functional class  X    X X 
Study Procedures           
  Dispense study drug   X   X  
  Start study drug    X    
  Study drug adherence     X X X 
  Study drug compliance     X X X 
  Adverse events  X   X X X 
  Study Termination       X 
Sub-study components           
Right heart catheterization (n= 20) X     X 
Cardiopulmonary Exercise Test (n= 10) X     X 
Covid testing for exercise test  
 (as required per lab requirement)  X     X 
Miscellaneous            
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   6        
Data Safety Monitoring Board    Semi-annually  
As per clinical practice guidelines, patients will be seen every three  to six  months with blood work and 
six-minute walk testing. These elements (visit, laboratory  draw, comprehensive metabolic panel, 
complete blood count, BNP, pregnancy test, 6 minute -walk distance, and NYHA functional class) will be 
collected as  part of routine medical care and abstracted from the medical record as research endpoints. 
The pregnancy test can be performed as either a blood or urine test. A blood -based pregnancy test is 
preferred; however, if a urine test is used then it must be per formed by  study personnel  and 
documented in the medical record. Echocardiograms are often part of routine medical care and will be 
abstracted from the medical record as research endpoints; however, the frequency may be influenced 
by the study. To avoid any concern about overlap, any echocardiogram occurring more frequently than 
annually will be considered research. It is anticipated that 1 of the 2 echocardiograms will fit this 
research definition. Other research elements include mass spectrometry for H 2 antagonists, the 
emPHasis -10 score, study procedures, and sub -study components.  
 
** These procedures will not be performed if the visit is done remotely.  
 
2  INTRODUCTION  
 
2.1 STUDY RATIONALE   
Although there has been substantial progress in the developm ent of medications to lower pulmonary 
vascular resistance in pulmonary arterial hypertension, th ere are currently no therapies that have been 
shown to have benefit for right heart failure in the a bsence of changes in right ventricular afterload.  
 
We are pursuing a novel approach that targets histam ine H2 receptors in patients with pulmonary 
arterial hypertension. Previous animal studies suggest that myocardial H2 receptors contribute to 
myocardial  fibrosis and are important mediators of heart failure. Our work has shown a l ower incidence 
of heart failure in community dwelling adults who use H2 receptor antagonists and a lower all -cause 
mortality in veterans with pulmonary hypertension who u se H2 re ceptor antagonists. A previous 
randomized controlled trial showed that famotidine improved b -natriuretic peptide, left ventricular 
morphology, and New York Heart Association Functional Class in participants with Heart Failure and 
Reduced Ejection Fraction (left heart failure). H2 receptor antagonism is an appealing therapeutic ta rget 
that is well aligned with current NIH priorities of repurposing existing, inexpensive, and well -tolerated 
medications for novel use in other disease states.  
 
We will study intermediate range clinical efficacy o f famotidine in participants with pulmonary 
hypertension. We will also assess the safety of famotidine in participants with pulmonary hypertension.  
 
There are two sub -studies proposed for the REHAB -PH tr ial. One sub -study involves cardiopulmonary 
exercise testing and the other sub -study involves invasive hemodynamic evaluation using right heart 
catheterization. Understanding the relationship between therapy, exercise response, and invasive 
hemodynamic ass essment is important for all pulmonary arterial hypertensi on (PAH) therapies and such 
studies are very common in trials of PAH -specific therapy. To date, nearly all therapeutic trials for 
participants with PAH have focused on medications intended to lower pulmonary vascular resistance 
and right heart afterload. Few studies have evaluated therapies intended to improve right heart fitness 
in the absence of changes in right heart afterload (<right heart ta rgeted therapy=). Targeting myocardial 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   7 histamine H2 rec eptors is one such therapy that is hypothesized to impact right heart fitness without 
changing right heart afterload. While the two proposed sub -studies are powered to detect plausible, but 
large differences in exercise response or invasive hemodynamic mar kers, these studies are not powered 
to detect small to moderate differences. The co -primary intent of these sub -studies is to begin to 
understand appropriate end -points in trials of right heart targeted therapy. This more exploratory 
motivation is intended  to complement but not supplant primary and secondary outcome measures 
including six -minute walk distance, BNP, and right ventricular struc ture and function by 
echocardiography in the current trial. Lessons learned from  resting, exercise, and invasive meas ures will 
be used to inform subsequent trials of right heart targeted therapy using famotidine and/or other 
compounds. We will study exercise response and invasive hemodynamic differences in participants with 
pulmonary hypertension with and without exposur e to famotidine.   
2.2 BACKGROUND   
H2 receptor antagonists were used successfully as a treatment for left heart failure and we showed a 
lower incidence of heart failure and differences in cardiac morpholog y with H 2 receptor antagonist use 
in a large observation al cohort. We have also shown H 2 receptor antagonist use is associated with 
improved mortality in a cohort of veterans with pulmonary hyperten sion. This raises the strong 
possibility that H 2 receptor antagonism is important in heart failure and likely alters the natural history 
of right heart failure.  
 
2.3 RISK/BENEFIT ASSESSMENT    
 
2.3.1  POTENTIAL RISKS  
 
Protection of participant identi ty is important and will be safeguarded by the use of study identifiers 
whenever possible, a secure comprehensive data manageme nt system, and safeguards for electronic 
data including password protection and encryption. In addition, all study staff will be trained in the 
importance and proper safeguards for pa rticipant9s privacy and confidentiality. All study personnel will 
be required to sign a confidentiality agreement as per our institutional review board requirements.  
 
All other study procedures including venipuncture, six -minute walk test, echocardiograph y, right heart 
catheterization, and cardiopulmonary exercise testing are part of the routine care for patients with PAH 
and will be familiar to all participants in the trial. Covid testing may be required prior to exercise te sting 
and presents  minimal risk  and discomfort to most people. Procedures with a small, but extant risk of 
serious complications including right heart catheterization and cardiopulmonary exercise testing are 
optional sub -studies for this trial. These risks will be described and procedur es will be done only in the 
setting of adequate staffing and resuscitation equipment to include at a minimum a registered nurse 
and cardiac catheterization technologist in the Catheterization Laboratory and a respiratory therapist or 
exercise physiologist in the Exercise Laboratory.  
 
Famotidine is very well tolerated and available over -the-counter where it is commonly marketed as 
Pepcid. Headaches and gastrointestinal upset have been reported a nd very rare instances of allergic 
reactions to the medication ( e.g. hives or difficulty breathing).  Adverse events will be collected and 
reviewed by a data safety monitoring board.  
 
Pregnant women and prisoners are excluded from study.  
 
2.3.2  POTENTIAL BENEFITS  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   8  
Participants in this trial have the potential to benefit f rom the intervention. If the hypothesis is 
confirmed than participants using famotidine may experience fewer signs and symptoms of right heart 
failure over the course of the study. The proposed trial also has the potential  to benefit the pulmonary 
arterial hy pertension community at -large given the possibility that the REHAB -PH trial will identify a 
readily available medication that is the first of its kind to target right heart failure directly. Resu lts from 
this trial could  inform future trials that benefit t he larger community of patients with a range diseases 
complicated by right heart failure (not related to PAH). Finally, results from the trial have the potential  
to benefit the health care system by providing a low cost adjunctive therapy for PAH patients, whose 
therapy currently represents a major expense for the health care system. These benefits may outweigh 
any risk associated with study procedures both for the study participant and the larger community.  
 
3 OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary    
To determine whether famotidine 
increases six -minute walk distance 
at 24 weeks in men and women 
with pulmonary arterial 
hypertension.  
 The primary end -point is th e change 
in six-minute walk distance (6MWD)  
between baseline and  24 weeks.  This 
will be compared between treatment 
groups.  The six -minute walk 
distance  is simple, 
reproducible, and well 
tolerated in patients 
with PAH.  The 6MWD 
has been the primary 
outcome measure for 
the majority of pivotal 
trials of PAH 
therapeutics because 
of its relationship to 
hemodynamic 
parameters, treatment 
outcome, and surviva l. 
Secondary    
To determine whether famotidine 
reduces BNP at 24 we eks 
 
To determine whether famotidine 
improves New York Heart 
Association (NYHA) functional class 
at 24 weeks  
 
To determine whether famotidine 
improves right ventricular 
morphology  at 24 weeks including 
improved right ventricular dilation 
and TAPSE  
 Secondary endpoints include the 
change in BNP, NYHA functional class, 
right ventricular basal diameter, 
TAPSE, emPHasis -10 score, and the 
frequency with which routine 
therapies for patients w ith PAH are 
escalated during the trial.  Secondary outcomes 
were chosen to better 
understand the impact 
of the intervention on 
various aspects of the 
treatment response  
including health -
related quality of life 
using disease specific 
validated tools . 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   9  
 
4 STUDY DESIGN  
 
4.1 OVERALL DESIGN  
 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
To determine whether famotidine 
improves health related quality of 
life as estimated by the emPHasis -
10 score  
 
To determine whether famotidine 
decreases the need to escalate PAH 
focused care (increased diuretics, 
escalating doses of pulmonary 
vasodilators, and/or adding an 
additional pulmonary vasodilator)  
 
Tertia ry/Exploratory    
Exercise sub -study:  
 
To determine whether famotidine 
increases maximal oxygen uptake 
in individuals with pulmonary 
arterial hypertension at 24 weeks  
 
To explore changes in other metrics 
of the exercise response (oxygen 
uptake, Ve/VCO2 ratio, total 
achieved wattage) with famotidine 
relative to placebo over 24 weeks.  
 
 
Right heart catheterization sub-
study:  
 
To determine whether famotidine 
increases str oke volume index at 24 
weeks  
 
To explore whether famotidine is 
associated with differences in 
wedge pressure, right atrial 
pressure, and/or pulmonary 
vascular resistance at 24 weeks The primary analyses will be the 
change in oxygen consumption (VO2) 
for t he exercise sub -study and the 
change in stroke volume index (SVi) 
for the right heart catheterization 
sub-study conducted using the 
intent -to-treat (ITT) population.  
 
Qualitative descriptions of other 
exercise and hemodynamic markers 
including mean, media n, and 
distribution will be presented 
stratified by treatment group . While the two 
proposed sub -studies 
are powered to detect 
plausible, but large 
differences in exercise 
response or invasive 
hemodynamic markers, 
these studies are not 
powered to detect 
small to moderate 
differences. The co -
primary intent of these 
sub-studies is to begin 
to understand 
appropriate end -points 
in trials of right heart 
targeted therapy. This 
more exploratory 
motivation is intended 
to complement but not 
supplant primary and 
secon dary outcome 
measures.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   10 This study is a Phase II , single -center, blinded, randomized, placebo controlled trial designed to test 
whether famotidine improves functional capacity and met rics of right heart failure relative to placebo in 
participants with pulmonary arterial hypertension over 24 weeks. In addition, there are two sub -studies. 
One sub-study involves  cardiopulmonary exercise testing and the other sub -study involves invasive 
hemodynamic evaluation using right heart catheterization.   
 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN  
 
The central aim of the proposed study is to determine whether famotidine improves right heart failure 
for participants with PAH. This includes the impact on functional outcomes (si x-minute walk distance  
and CPET ), patient -reported outcomes (emPHasis -10 questionnaire , Appendix 1 ), and metrics of right 
heart stress and  strain (echocardiography, BNP, and invasive hemodynamics). Right heart failure is the 
key driver of morbidity and mortality for patients with PAH. Treatm ents for pulmonary vascular disease 
have been developed over the last twenty years; however, there are  no cardiac -targeted therapies for 
this or any other form of right heart failure. Our work and the work of others strongly suggests that H2 
receptor signaling is important in the pathogenesis and progression of heart failure and antagonism of 
the H2 recept or may improve the natural history of heart failure and pulmonary hypertension. The 
potential importance of this approach is augmented by the fact that famotidine is an extremely well -
tolerated and inexpensive over -the-counter medication for gastro -esophageal reflux. Inexpensive and 
well-tolerated medications are important for all diseases; however, are particularly needed for patients 
with pulmonary vascular disease where current medicatio ns targeting the pulmonary vasculature are 
notable for their extreme  expense and high side effect profile.  
  
4.3 JUSTIFICATION FOR DO SE 
 
Participants will receive eithe r 20mg of famotidine or placebo and  will take one tablet,  once daily  for 24 
weeks . This dose was chosen because it is a standard clinically available dose resulting in effective 
antagonism of the H2 receptor. This dose was included in a previous observational study evaluating 
famotidine in heart failure with reduced ejection fraction.  
 
Famotidine is widely available, inexpensive, and has relatively few side effe cts. This belies an 
intervention that is well tolerated with minimal impact on the health care  system. If we show efficacy, 
this represents a high value addition for patients and  society.  
 
The choice of 24 weeks was not arbitrary. A previous randomized controlled trial showed that 
famotidine relative to an active control (teprenone) improved b -natriuretic peptide, left ventricular 
morphology, and New York Heart Association Functional Class over 24 weeks in participant s with Heart 
Failure and Reduced Ejection Fraction (left heart failure). 
 
To avoid contamination of the placebo arm by participants taking over -the-counter H2 receptor 
antagonists for acid reflux, we  will provide all participants with a comprehensive lis t of H2 receptor 
antagonists to avoid during the trial. We will also provide Calcium Carbonate and Omeprazole for acute 
and chronic control of acid reflux symptoms during the trial. This will help to m inimize inadvertent 
contamination of the control arm through self -treatment of acid reflux.  
 
4.4 END OF STUDY DEFINITION  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   11 A participant is considered to have completed the study if  he or she has completed all phases of the 
study including the last visit shown i n the S chedule of Activities (SoA), Section 1.3 . 
 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
In order to be eligible to participate in this study, an individual must meet all of the following  criteria:  
 
1. Male or female, age 18 to 80  
2. WHO Group 1 Pulmonary Arterial Hypertension  
3. NYHA Functional Class II, III, or IV at screening*  (See Appendix 2 for Functional Class Decision 
Aid)  
4. Stable dose of pulmonary vasodilators for 30 days prior to randomization  
5. Right heart catheterization within five years demonstrating a mean pulmonary arterial pressure  
of g 25 mmHg , an occlusion pressure of f 15 mmHg , and a pulmonary vascular resistance of g 3 
wood units  
o Participants with a right heart catheterization within five years demonstrating a mean 
pulmonary arterial pressure of g 25 mmHg and occlusion pressure of 15 - 20 mmHg will 
be considered for inclusion if the pulmonary vascular resistance g 9 wood units and they 
are being treated with pulmonary arterial hypertens ion specific therapy  
6. Able to walk with/without a walking aid for a distance of at  least 50 meters  
 
5.2 EXCLUSION CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in this study:  
 
1. Pregnant or lactating  
2. Non-group 1 pulmonary hypertension or veno- occlusive disease  
3. History of interstitial lung disease, unless subject has co llagen vascular disease and has 
pulmonary function testing conducted within 12 months demonstrating a total lung capacity  or 
vital capacity of g 6 0 % 
4. Has received or will receive an investigational drug, device, or st udy within 30 days or during the 
course of study  
5. Left sided myocardial disease as evidenced by left ventricular ejection fraction < 40%  
6. Any other clinically significant illness or abnor mal laboratory values (measured during the 
Screening period) that, in the opinion of the Investigator, might put the subject at risk of harm 
during the study or might adversely affect the interpretation of the study dat a 
7. Anticipated survival less than 1 ye ar due to concomitant disease   
8. Regularly taking an H2 receptor antagonist within 30 days  of enrollment  
9. Creatinine clearance of < 30 mL/min  
10. History of bariatric surgery  
11. Current treatment for HIV  
 
Individuals with thrombocytopenia (<20,000/microliter), coa gulopathy (INR >3), hyperkalemia (>6), 
hypokalemia (<2.5), or hyponatremia (125) cannot participate in the RHC sub -study. In addition, 
participants with known anatomic barriers to IJ placement, a l atex allergy, or infection at the insertion 
site will be excluded from this sub -study.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   12  
Individuals with known, recent exercise associated syncop e will be exclude from the cardiopulmonary 
exercise testing sub -study. In addition, individuals with recent my ocardial infarction, unstable angina, 
uncontrolled arrhythmia, severe valvular stenosis, decompensated heart failure, active endocarditis, 
acute myocarditis or pericarditis, acute aortic dissection, or marked electrolyte abnormalities will be 
excluded from  the CPET sub -study.  
 
5.3 LIFESTYLE CONSIDERATIONS  
Not applicable.  
 
 
 
 
5.4 SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in the clinical tria l but are not 
subsequently randomly assigned to the study intervention or entered  in the study. This includes 
participants who undergo baseline studies, but who have not been randomized, and for whom the 
baseline evaluation inform clinical concern that they are not appropriate for the study as evidenced by 
meeting an exclusion criteria  or failing to meet an inclusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of scree n failure participants, to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any serious adverse event (SAE).  
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
All potential subjects for the REHAB -PH Trial will be recruited from the University of Washington 
Pulmonary Vascular Disease Program.  
 
Potential participants seen in the UW Pulmonary Vascular Disease Clinic  will be  pre-screen ed using the 
electronic medical record. Potentially eligible participants  will be recruited at the time of their clinic visit 
or if time permits, they will  receive a one page letter via mail describing the study  and/or a phone call 
from the study coordinator  in anticipation of their next visit to clinic. During the potential participan t9s 
clinic visit, they will be approached and invited to participate in the REHAB -PH study by the study team 
at the UW Pulmonary Vascular Disease Clinic. A research coordinator will follow -up with any patient 
who is willing or c onsidering participation in the study. This may include scheduling a baseline visit in -
person at the clinic visit and/or following up by telephone.  
 
Retention is a vital consideration for the success of th e study. As we have done in other studies, we will 
maximize retention by careful training of clinical re search staff on best practices for retaining 
participants. Staff conducting adherence and retention efforts will be trained to conduct effective 
informe d consent to assure that participants fully understand the demands and nature of the study 
before they enroll. Clinical center staff will carefully review study requirements with the subjects, 
explain the concept of random assignment and what each tr eatmen t involves, and stress the importance 
of follow -up assessment even if they are not adhering to their assigned treatment. Participants will be 
nominally remunerated for their participation to offset travel and parking costs. Clinic staff will, at each 
visit, convey our appreciation for their participation in the study.  Concerns about individual participants 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   13 will be raised with direct involvement, such as phone calls, by the PI and study center staff as needed to  
facilitate retention.  
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION(S)  ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION DESCRIPTION  
 
The study drug is Famotidine , a histamine  H2-receptor antagonist . Participants will receive either 20mg 
of famotidine or placebo. H2 receptor antagonists are widely available, over -the-counter medications 
and acid reflux (their current indication) is common. Over -dose with an H2 receptor antagonists has not 
been described; however, to avoid contamination of the placebo arm by participants taking over -the-
counter H2 receptor antagonists for acid reflux, we will provide all participants with a comprehensive list 
of H2 receptor antagonists to avoid during the trial. We will also provide Calcium Carbonate and 
Omeprazole for acute and chronic control of acid reflux symptoms during the trial. This  will help to 
minimize inadvertent contamination of the control arm t hrough self -treatment of acid reflux. We will 
employ adherence and retention principles and procedures that  are standard in the cardiology trials unit 
at the University of Washington . In addition, the degree to which this approach is effective will be 
evaluated through a mass -spectrometry based assay for the presence of any H2 receptor antagonist in 
the blood of study participants at the end of the trial. Ideally H2 receptor  antagonists will be seen in 
100% of the assays in the active arm and 0% in the con trol arm. Significant deviation from this expected 
finding will be considered in the inference on results.  
 
The placebo contains an inactive excipient powder and to preserve  study blinding, the placebo tablets 
will be  identical in size, shape, color, and appearance to the famotidine tab lets.  
 
Famotidine and matching placebo tablets will be in bottles containing 91 tablets. Foll owing enrollment 
and randomization, each subject  will receive one bottle to cover the first 12 weeks o f the study, which 
will be subject -specific. The site staff will instruct the subject to take one tablet daily. At Week 12, 
subjects will receive another bottle to cover the last 12 weeks of the study.   
6.1.2  DOSING AND ADMINISTRATION  
 
Participants will be randomized to either take a placebo or a 20 mg tablet of famotidine, per oral, once a 
day for 24 weeks.  
 
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY  
 
6.2.1  ACQUISITION  AND ACCOUNTABILITY  
 
Harborview Medical Center Investigational Drug Services (HMC IDS ) will distribute famotidine and 
placebo tablets for the University of Washington Medical Center Investigational Drug Services (UWM C 
IDS) to dispense. U WMC IDS will store  the famotidine  and placebo  and dispense the pills to the study 
coordinator who w ill then give them to the subjects. The subjects will self -administer the pills at home 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   14 and bring any unused pills back to the study coordinator. Returned pills will be  logged and  then dispo sed 
of by  UWMC  IDS.  
 
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
Kirkland Signature will manufacture Famotidine 20 mg tablets. HMC IDS  will provide famotidine 20mg 
placebo capsules (Placebo) and over -encapsulation of famotidine 20  mg tablets (Famoti dine)  to the 
University of Washington Medical Center Investigation al Drug Services (UWMC IDS) . UWMC IDS will 
place the tablets in 91 count bottles  and will label the bottles  with blinded prescription labels prior to 
distribution.  
 
 
6.2.3  PRODUCT STORAGE AND STABILITY  
 
The bottles of famotidine and matching placebo should be stored at controlled room temperature of 
15°C 3 30°C (59°F 3 86°F). Each bottle will have an expiration date.  
 
 
6.3 MEASURES TO MINIMIZE BIAS : RANDOMIZATION  AND BLINDING  
 
Subjects will be ran domly assigned in a 1:1 ratio to one of two arms  using permuted block 
randomization : (1) placebo or (2) famotidine. Subject randomization will be stratified by NYHA/WHO 
Functional Class (NYHA/WHO Functional Class II versus Class III/IV) to ensure balanced representation of 
this important marker of severity. A randomization code will be computer -generated by contract 
research organization (CRO) Axio Research , LLC. Subjects meeting study entry criteria will be randomized 
via an interactive web response system (IWRS). The randomization schedule will be generated by the 
randomization statistician at Axio Research (who is not on the project team) or designee and maintained 
in a secure and limited -access location separate from the study investigator and members of  the project 
team. The study subject, investigative staff, the Sponsor, the Sponsor study team (includes contractors 
and vendors), excluding the unblinded study site pharmacist will be blinded to treatment assignments 
during the study.  
 
6.4 STUDY INTERVENTION COMPLIANCE  
 
Study drug counts will be conducted at all study visits. Per protocol cohorts include 80% compli ance with 
the once daily intervention. A total of 91 tablets will be provided at each study visit. A count of unused 
medications at the 12 and  24-week follow -up visit will be logged in a drug accountability log and used to 
determine compliance with the intervention.  
 
6.5 CONCOMITANT THERAPY  
 
For this protocol, a prescription medication is defined as a medication that can be prescribed only  by a 
properly authorized/licensed clinician. Medications to be reported in the Case Report Form (CRF ) are 
concomitant prescription medications, over -the-counter medications and supplements.  
 
Participants are prohibited to take H2 receptor antagonists during the trial.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   15  
Research pharmacists will review the study participant9s m edications listed in their medical record and 
advise them about the timing of admini stration of their current medications with famotidine and the 
acid reflux concomitant medications provided. This will occur at the initial visit and as needed for any 
follow -up visits that have any  new  medication s added  between the visits.  
 
According to p harmacokinetic analyses, single doses of famotidine 20mg raised intragastric pH to mean 
values of 5.0 (similar for when doses were given in the ev ening or after breakfast). There were no 
cumulative effects with repeated doses. However, there are many studi es that have shown 
tachyphylaxis with repeated doses of H2RAs occurring after approximately a week of therapy. Repeated 
doses of H2RAs are associated with decreased time of gastric pH maintained above 4.0.   
 
The impact on the availability of pulmonary vasodilators is as follows:  
 
" Sildenafil: no interaction  known ; delayed rate of absorption with high -fat meals but not antacids 
(time delay 1 hr, reduced maximum concentration by 29%)  
" Tadalafil: no significan t interaction  known ; antacids reduced rate s of absorption with  no change in 
overall exposure; no significant effects observed with the co -administration of nizatidine 300mg  
" Riociguat: no information available specifically with H2RAs; however, concurrent use with antacids 
is associated with up to 50% reduction in riociguat maximum serum conc entration and 25% 
reduction in exposure; recommended to separate the administration of antacids and riociguat by 
at least 1 hr; specific mechanisms for these interactio ns are unknown but riociguat solubility is pH -
dependent, and therefore, increases in gastric pH may be partially responsible  
" Bosentan: no interaction 
" Ambrisentan: no interaction  
" Macitentan: no interaction  
" Oral treprostinil: no interaction; bioavail ability is increased by high fat, high calorie meals by up to 
49% but not known to be impacted by acid suppression  
" Selexipag: no interaction; time to peak concentration may be delayed with food but not known to 
be impacted by acid suppression.  
 
Referen ces:  
Famotidine [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2018.  
McRorie JW, Kirby JA, Miner PB. Histamine2 -receptor antagonists: rapid development of tachyphylaxis 
with repeat dosing. World J Gastrointest Pharmacol Ther . 2014; 5(2):57 -62. 
Adempas (riociguat) [package insert]. Whippany, MJ: Bayer  HealthCare Pharmaceuticals Inc., 2013.  
Interactions. Lexicomp. Wolters Kluwer Health, Inc. Riverwoo ds, IL. Available at: http://online.lexi.com. 
Accessed March 2019.  
 
6.5.1  RESCUE MEDICINE  
Not applicable.   
 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
 
7.1 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY  
Participant s are free to withdraw from participation in the study at any time upon request.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   16 An investigator may discontinue  or withdraw a participant from  the study for the following reasons : 
 
" Pregnancy  
" Serious Adverse event(s) related to the trial medication  
" Any relevant deterioration in the health of the subject (AE s, vital signs, laboratory p arameters).  
" Protocol violation  
" Subject9s inability to stay on the study drug or off other H2 blockers  
" Subject withdrew consent  
 
The reason for participant discontinuation or withdrawal from the study will be recorded on the Case 
Report Form (CRF).  
 
7.2 LOSS TO FOLLOW -UP 
 
A participant will be considered lost to follow -up if he or she fails to return for a scheduled visit and is 
unable to be contacted by the study site staff.  
 
The following actions must be taken if a participant fails to return to the cl inic for a required study visit:  
" The site will attempt to contact the participant and reschedule the missed visit within a week 
and counsel the participant on the importance of maintaining the assigned visit schedule and 
ascertain if the participant wishes to and/or should continue in the study.  
" Before a participant is deemed lost to follow- up, the investigator or designee will make every 
effort to regain contact with the participant (where poss ible, 3 telephone calls and, if necessary, 
a certified letter to the participant9s last known mailing address or local equivalent methods). 
These contact attempts should be documented in the participant9s study file.  
" Should the participant continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason of lost t o follow -up. 
 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
 
8.1 EFFICACY AND SAFETY ASSESSMENTS  
 
At the baseline visit participants will be consented and in clusion and exclusion criteria will be assessed 
for e ligibility. Participants will then undergo a standardized clinical assessmen t with medical history, 
symptom assessment including NYHA functional class, vital signs  (includes height, blood pressure, heart 
rate, oxygen saturation), weight,  and physical exami nation. Demographics will be collected. A blood 
draw will include safety laboratories including comprehensive metabolic panel, complete blood count, 
BNP, and pregnancy test (for pre -menopausal women) . The pregnancy test can be performed as either a 
blood o r urine test. A blood -based pregnancy test is preferred; however, if a urine test is used then it 
must be performed by  study personnel and documented i n the medical record.  All participants will  have  
serum collected for mass -spectrometry  at the end of the  study  to evaluate for contamination of the 
study  design  by individuals taking over -the-counter H2 receptor antagonists. Serum, plasma, and blood 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   17 for RNA isolation will be collected and stored for participants. Subjects wi ll have an option to opt -out of 
this additional research blood sample. All participants will have a transthor acic (TTE) echocardiogram 
and emPHasis -10 measure of health- related quality of life. They will also complete a 6 minute walk 
distance (6MWD) at their baseline visit . Distance, BORG dyspnea scores, peak heart rate, oxygen 
saturation , and heart rate recovery at one minute  will be collected to characterize the walk.  
 
Participants who are not participating in the right heart cathete rization or exercise sub -studies will be 
randomized and  study drug will be dispensed at this visit. Participants will be  instructed to take one 
tablet daily (20 mg of famotidine or placebo)  the following day which will represent day zero and entry 
into the study . An antacid (Calcium Carbonate) and proton pump inhibitor (Omeprazole), both over -the-
counter medications, will be provided by a study physician to participants as needed for short and long 
term heartburn control in an effort to try and minimize contamination of the study question by 
inadvertent H2  receptor antagonist use by participants attempting to self -treat heartburn with over -the-
counter medications.  
 
Individuals who are participating in the right heart catheterization or exercise sub -studies will be 
randomized and study drug will be dispensed  at their last baseline study assessment. These participants 
will also be instructed to take one tablet daily (20 mg of famotidine or placebo) the day following 
randomization and dispensing of the study drug.  
 
Regardless of the participation in sub- studies , all baseline assessments need to be completed within 14 
days prior to the start of study drug (not inclusive of the date the first dose of study drug is taken). The 
day study drug is taken will be considered day 0.   
 
Week 4 phone call will be on day 28 ± 7. This visit will address study drug adherence and adverse events.  
 
Week 12 visit will occur at day 84 ± 7. This visit w ill include a standard clinical assessment with a 
symptom assessment including NYHA Functional Class, vital signs, weight, and physical examination. 
Participants will also have a 6 -minute walk distance, emPHasis -10 score, evaluation for adverse events, 
evaluation for medication and study drug compliance, and dispensation of study drug.  Due to the 
COVID -19 pandemic, this visit can be done as telehealth or in -person based on current COVID -19 levels 
in the community and patient preference. If visit is done as telehealth it will include a symptom 
assessment including NYHA Functional Class, emPHasis -10 score, evaluation for adverse even ts, and 
evaluation for medication and study drug compliance. The U WMC Investigational Drug Service will ship 
the next supply of study medication to the subject via FedEx overnight shipping to coincide with this 
visit. In person visits will be encouraged.  
 
Week 24 visit will occur at day 168 ± 7 and will inc lude all components included in the baseline visit:  a 
standard clinical assessment with a symptom assessment including NYHA Functional Class, vital signs, 
weight, and physical examination. Participants w ill also have a 6 -minute walk distance, an 
echocardiogram, emPHasis -10, evaluation for adverse events, evaluation for medic ation and study drug 
compliance, and a blood draw including a comprehensive metabolic panel, complete blood count, BNP, 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   18 and pregnancy  test if indicated. The pregnancy test can be performed as either a blood or urine test. A 
blood -based pregnancy test is preferred; however, if a urine test is used then it must be performed by  
study personnel  and documented in the medical record.  All par ticipants will have serum collected for 
mass -spectrometry at the end of the study  to evaluate for contamination of the study question by 
individuals taking over -the-counter H2 receptor antagonists. Serum, plasma, and blood for RNA isolation 
will be collect ed and stored for participants.  
  
Adverse events and concomitant medications will be assessed a nd collected at all visits.  
 
Optional Right Heart Catheterization (RHC) Evaluation: Subjects  will have the option to take part in the 
RHC portion of the study t hat will be performed within 14 days of the Baseline Visit and  within 7 days of 
the Week 24 Visit. The baseline visit must be done while not taking study drug and the week 24 visit 
must be done while taking study drug. This is a procedure which is performed for all patients  with PAH. 
The purpose of this optional evaluation is to track changes in the measurements of the subjects9 heart 
and lungs that might be related to study treatment with famotidine. 1% lidocaine local anesthesia will 
be used.  It will tak e 3-4 hours to complete the right heart catheterization. On  the day of the right heart 
catheterization, subjects will check into the cardiac catheterization laboratory at the University of 
Washington Medical Center. A nurse will check the su bject9s vital s igns and basic bloodwork to make 
sure that the procedure is safe to perform. Once this is done, subjects will go into the cardiac 
catheterization laboratory where Dr. Leary will numb the area for the procedure with lidocaine. This will 
typically be the rig ht side of the neck. After numbing the area, Dr. Leary will place a catheter into a vein, 
the right atria, right ventricle, and pulmonary artery and measure pressures at each position and check 
to see how much blood the heart is pumping. The process of ins erting the catheter and taking 
measurements normally takes approximately 20 -30 minutes. After these measurements, the catheter 
will be removed, a nurse will hold pressure on the are a to ensure that there is no bleeding, and the 
subject will then be free to  go. 
 
Optional Cardiopulmonary Exercise Test (CPET) Evaluation: Subjects will have the option to take part in 
the CPET portion of the study that will be performed within 14 days of the Baseline Visit and within 7 
days of the Week 24 Visit. The baseline visit mus t be done while not taking study drug and the week 24 
visit must be done while taking study drug. CPET will be don e via bicycle ergometry and will be 
performed in the Exercise Testing Laboratory of the UW Lung Function Testing Center. This is a routine 
clinical test used by pulmonologists and cardiologists, but is not routinely done for all individuals with 
PAH. This test measures how the body tolerates physical activity.  Due to the Covid 19 Pandemic, the 
Lung Function Testing department at UWMC is requirin g Covid testing prior to any procedures done in 
the lab. As long as this requirement is in place, you will be given a phone number to call to arrange 
testing at a drive through testing site within 72 hours of your appointment. At the drive through site, 
you will stay in your car and a nurse will use a nasal swab (like a long Q -tip) inserted into your nose and 
back of throat to collect cells which will be sent to the lab. You will be notified in the ev ent of a 
positive test result.  
On the day of the test, su bjects will check into the Lung Function Testing Center at the University of 
Washington Medical Center. They should wear clothing  suitable for exercise. A respiratory therapist wil l 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   19 check the subject9s vital signs and conduct breathing tests. After this th ey will hook up an EKG, monitor 
the subject9s oxygen via a probe on their finger, and place a neoprene mask over their nose and mouth. 
These will measure a number of important exercise characteristics. Subjects will then ride a stationary 
bicycle in the ex ercise lab. The test is variable in length and designed to pus h the subject to exercise as 
hard as they can tolerate in a highly supervised setting. Most participants exercise for 5 -15 minutes with 
increasing resistance on the stationary bicycle. This is f ollowed by a <cool -down= period on the bicycle. 
When the subject is done, a respiratory therapist wi ll continue to monitor the subject for 5 -10 minutes 
at rest. After this time , subjects will be free to go.    
 
Participants in the invasive hemodynamic and cardiopulmonary exercise testing (CPET) sub -studies will 
have the option to do both tests on the same day or separate days, but within the 3 days of the final 
visit.    
 
8.2 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
 
8.2.1  DEFINITION OF ADVERSE EVENTS  (AE)  
 
Any unfa vorable and unintended sign (including an abnormal laborato ry finding), symptom or disease 
temporally associated with the use of a medical treatment or procedure, regardless of whether it is 
considered related to the medical treatment or procedure.  
 
8.2.2  DEFINI TION OF SERIOUS ADVERSE EVENTS  (SAE)  
 
Any AE that results in any of the following outcomes:  
" Death  
" Life -threatening  
" Event requiring inpatient hospitalization or prolongation of existing hospitalization  
" Persistent or significant disability/incapacity  
 
8.2.3  CLASSIFICATION OF AN ADVERSE EVENT  
8.2.3.1  SEVERITY OF EVENT  
 
AEs are graded according to the following scale:  
Mild:  An experience that is transient, & requires no special treatmen t or intervention. The 
experience does not generally interfere with usual daily activiti es. This includes transient 
laboratory test alter ations.  
Moderate : An experience that is alleviated with simple therapeutic treatm ents. The experience 
impacts usual daily activities. Includes laboratory test alterations ind icating injury, but without 
long -term risk.  
Severe:  An experience that requires therapeutic intervention. The experience interrupts usual 
daily activities. If hospitalization (or prolongation of hospitalization) is required for treatment it 
becomes an SAE.  
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   20 8.2.3.2  RELATIONSHIP TO STUDY INTERVENTION  
 
The study uses the following AE attribution scale:  
Definite:  AE is clearly related to study drug or a study procedure  
Probable:  AE is likely related to study drug or a study procedure  
Possible:  AE is possibly related to study drug or a study procedu re  
Unlikely:  AE is doubtfully relate d to study drug or a study procedure  
Unrelated:  AE is clearly not related to study drug or a study proc edure  
 
8.2.3.3  EXPECTEDNESS  
 
Expected AEs associated with famotidine include:  
Headaches  
 
Although expected AEs associated with right heart catheterization are uncommon, they include:  
Pain/discomfort, nausea, vomiting, redness, irritation, b ruising, or development of a small 
hematoma/bleeding, allergic reactions in rare instances (e.g. hives or difficulty breathing from l idocaine 
or catheters) , infection, damage to nearby structures (artery, vein, nerve, lung), hypertensive crisis, 
hypotension, chest pain, bronchospasm, arrhythmia, dizziness/syncope, or death (Hoeper et al., 
Complications of right heart catheterization procedures in patients wi th pulmonary hypertension in 
experienced centers, J Am Coll Cardiol; 48: 2546 -52, 2006).  
 
Although expected AEs associated with exercise testing are unco mmon, they include:  
Changes in blood pressure and heart rate, fatigue, discomfort, musculoskeletal inju ry, syncope, 
arrhythmia, heart attack, or stroke (Skalski et al. The safety of cardiopulmonary exercise testing in a 
population with high -risk cardiovascular diseases, Circulation; 126:2465 -72, 2012).  
 
Expected AEs associated with the underlying natural hi story of pulmonary arterial hypertension or PAH 
therapies over a 24 -week study include:  
Dizziness, syncope, leg swelling, abdominal swelling, chest pa in, shortness of breath, hypoxemia, 
hemoptysis, nausea, vomiting, diarrhea, jaw pain, flushing, joint pain , muscle pain, infection, arrhythmia, 
heart failure, pericardial effusion/tamponade, cirrhosis, thrombosis or embolus, stroke, cardiac arrest, 
or sudden cardiac death.  
8.2.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The study team will record  all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for non -serious AEs) or 14 days (for SAEs) after the last day of study 
participation.  AEs are identified at any of the three in -person visits, during a phone visit, during a study -
based procedure (e.g. heart catheterization or cardiopulmonary exercise test) or when notified outside 
of the normal visit structure by a participant or surrogate.  Events will be followed until resolution or 
stabilization.  
 
8.2.5  ADVERSE EVENT REPORTING  
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   21 Deaths and u nexpected, but definite, probable, or possibly -related SAEs are reported to the PI and 
DSMB within 48 hours through the use of an e- mail transmitted SAE report form copied to the PI, 
executive secretary of the DSMB, an d DSMB Chair.  
 
In addition, all events that meet the definition of an una nticipated problem (in the PI9s opin ion) should 
be reported to the UW IRB within 10 days using the Zipline Online portal.  
 
An unanticipated problem is a problem or event that meets all of the following criteria:  
" Unexpected 3 The harm (or potential harm) is inconsistent with risk information previously 
reviewed and approved by the Institutional Review Board (IRB) in terms of nature, severity, or 
frequency as well as the characteristics of the study population.  
" Related or probably related to participation in the resear ch; 
o Probably related: There is a reasonable probability (more likel y than not) that the 
incident, experience or outcome may have been caused by the proc edure s involved in 
the research, or that it is associated with the use of any drug, biologic, or medical device 
that is part of the research.  
" Suggests that the research places (or did place) one or more subjects or others at a greater risk  
of harm than was prev iously known or recognized. This includes physical, psychological, 
economic, educational advancement, or social harm.  
Reports are required within 24 hours  for qualifying medical problems covered by the UW Human 
Subjects Assistance Program (HSAP), a breach of confidentiality, or inappropriate use of protected 
health information.  
In addition, the IRB requires a report within 10 days fo r serious non- compliance, continuing non -
compliance (serious or non -serious), emergency deviation from IRB approved procedures to eliminate  
an apparent hazard to subjects or others, complaints that cannot be resolved by the research team, 
audit notification from a federal agency, information that indicates a new potential risk (e.g. new 
publication), and all DSMB report s.  
 
Expected S(AE)s are not required to be reported to the UW IRB outside of continuing review.  
 
 
8.2.6  REPORTING E VENT S TO PARTICIPANTS  
 
Participants will be updated with any learned information d uring the study that may affect their 
willingness to participa te.  
8.2.7  EVENTS OF SPECIAL INTEREST  
Not applicable.  
 
8.2.8  REPORTING OF PREGNANCY  
 
Pregnancy and the post -partum period is a highly dangerous and volatile time for women with 
pulmonary arterial hypertension and as a result participants who are pregnant, lactating, or have 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   22 evidence of dynamic disease with pulmonary vasodilator adjus tment within 30 days of randomization 
will not be included. It is also possible that harmfu l side effects that are not yet known could happen t o 
both the mother and unborn or breast -feeding child.   
 
The investigator must be notified immediately if the subject  become s pregnant and they will be 
withdrawn from the study. This is anticipated to occur  uncommonly if ever. The clear clinical 
recommendation in pulmonary arterial hypertension is dual -method contraception and the risk of death 
with pregnancy is p rohibitive. Unintended or intended pregnancy is a very rare event in the pulmonary 
vascular disease clinic.  
 
9 STATISTICAL CONSIDERATIONS   
 
9.1 STATISTICAL HYPOTHESES  
 
Primary Efficacy Endpoint(s): The primary endpoint is the difference in 6 -minute walk distanc e.  
 
Secondary Efficacy Endpoint(s):  The secondary endpoint is the difference between treatment groups in 
BNP, NYHA functional class, TAPSE, right ventricular basa l diameter, emPHasis- 10 score, and number of 
participants with an escalation of routine clini cal treatments for PAH for each visit . 
 
We hypothesize that famotidine use in individuals wi th PAH will improve 6 -minute walk distance over 24 
weeks relative to placebo.  
 
We further hypothesize that over 24 weeks famotidine  use in individuals with PAH will lower BNP, 
improve the NYHA functional class, increase the TAPSE, diminish the r ight ventricular basal diameter, 
improve the emPHasis -10 score, and minimize the need to e scalate routine treatment for PAH (diuretics 
and pulmonary vasodilators).  
  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   23 9.2 SAMPLE SIZE  DETERMINATION  
 
The primary endpoint is the change in six -minute walk distance . The study was powered to detect a 
difference of 31.9 meters. A 31.9 meter improvement in 6MWD is well aligned with established 
thresholds for a minimally important difference in patient reported outcomes. The 6MWD was chosen 
because 6MWD is a surrogate f or patient -centered outcomes and was the primary endpoint in labeling 
trials for most of the medications used to treat pulmonary arterial hypertension (PAH).  
 
The field is appropriately shifting toward larger event driven trials; however, we did not feel  a larger 
event driven trial of famotidine was warranted at this jun cture. The current proposal is the first 
randomized evaluation of this drug and this pathway in individuals with right heart failure and/or PAH 
and a smaller Phase II trial was felt to be a  more appropriate next step.  
 
For the RHC sub -study, the initial sample size was set at 10 participants based on the following power to 
detect large differences.  
 
Size of difference  SV index (mL/m2)  Total sample size  n per group  power  
Large  20 10 5 0.87  
Medium -high  15 10 5 0.67  
Medium -low 10 10 5 0.36  
Small  5 10 5 0.13  
 
As the study progressed, recruitment into this invasive ar m appeared to be more feasible and the 
sample size was increased to 20 participants.  
Size of difference  SV index (mL/m2)  Total sample size  n per group  power  
Large  20 20 10 0.99  
Medium -high  15 20 10 0.95  
Medium -low 10 20 10 0.68  
Small  5 20 10 0.23  
 
 
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   24 9.3 POPULATIONS FOR ANALYSES  
Intent -to-Treat Population: All subjects who are randomized will comprise the intent -to-treat (ITT) 
population. The ITT population will be analyzed for the primary and secondary endpoint analyses and will 
comprise the safety population used for all safety analyses.  
Per Protocol Population: Subjects in the ITT population who se famotidine medication reconciliation 
suggest adherence to study drug for 80% or more of administered doses will be evaluated as the per 
protocol population. The per -protocol population will be used in the sensitivity analyses of the primary 
and secondary endpoints. A second per protocol population will include participants for whom H 2 
receptor antagonists are detected by Mass Spectrometry at the final visit relative to those for whom H 2 
receptor antagonists are not detected.  
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
Except where otherwise noted, all tests will be two -sided and statistical significance will be determined at 
the 0.05 level.  
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
 
The primary endpoint is the difference between treatment groups in the change of 6 -minute walk 
distance (6MWD) between baseline and 24 weeks. Linear regression will be performed w ith the change 
in 6MWD between baseline and 24 weeks as outcome and treatment  group as the primary predictor of 
interest, adjusted for baseline 6MWD and baseline NYHA functional c lass as the stratification variable. 
The estimate of the treatment effect will be provided with associated 95% confidence interval (CI).  
 
Missing 6MWD at  24 weeks will be imputed as follows. Subjects known to be dead before the 24 week 
assessment will have zero imputed for their 24 week 6MWD. Missing 24 week 6MWD for subjects who 
are alive will be imputed using multiple imputation. The imputation model wil l have prognostic variables 
as the predictor variables. Prognostic variables will include age, gender, and etiology of pulmonary 
hypertension, baseline six minute walk test, baseline right ventricular diameter, and baseline BNP. The 
multiple imputation wil l use Markov Chain Monte Carlo (MCMC), which assumes that the varia bles in 
the imputation model have a joint multivariate normal distribution (MVN). The number of imputations 
to be performed will be 100. One hundred is selected because it is not too large that it requires heavy 
computations and is not too small (such that the Monte Carlo error is still small enough at around 0.1 
times the standard deviation). The <proc mi= procedure in SAS will be used to impute the missing 
observations.  
 
Although every eff ort will be made to avoid missing data, a range of approaches to missing 6MWD will 
be considered as sensitivity analyses representing a range of conservative and anti -conservative biases 
to describe the range of possible differences.  
 
Sensitivity Analyses of the Primary Endpoint  
Sensitivity analyses of the primary endpoint will include:  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   25 " a linear regression model using a worst case scenario (WCS) method of imputation  
" a linear regression model of the 24 week 6MWD without imputation (complete case analysis)  
 (1) The worst case scenario method of imputation will impute zero for all missi ng 6MWD at week 24.     
 (2) The linear regression method will model the 24 week 6MWD on treatme nt assignment, adjusting for 
baseline 6MWD and baseline NYHA class using least squares and robust standard error estimates. For all 
methods, treatment effect estimates and 95% CIs will  be presented.  
 
Additional Analyses of the Primary Endpoint  
Additional analyses of the relative change in 6MWD will in clude the proportion of participants who 
achieve a minimally important change in 6MWD of 31.9 meters or greater. To test the null hypothes is 
that there is no difference between the treatment groups, logistic regression adjusted for the NHYA 
functional class (stratification variable) will be used. The difference betw een treatment groups will be 
provided with associated 95% CI. Subjects missin g the 24 week 6MWD will not be counted as having 
achieved a minimally important change.  
 
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
 
Summary statistics (mean, standard deviation, median and range) of BNP (untransformed and log -
transformed), NYHA functional class, right heart strain, TAPSE, right ventricular basal diameter, 
emPHasis -10 score, and number of participants with an escalation  of routine clinical treatments for PAH 
for each visit will be presented by treatment group. Change in these param eters (log -transformed value 
for BNP) will be evaluated between the treatment groups using linear reg ression adjusted for the value 
at baseline and NYHA functional class (stratification variable). The difference with 95% CIs will be  
reported.  
 
The BNP is expected to vary by NYHA functional class. An additional sens itivity analysis will be 
performed with the difference of log -transformed BNP between baseline and week 24 as the outcome, 
with the predictor variables being baseline log -transformed BNP, treatme nt group, baseline NYHA 
functional class, and an interaction term between treatment group and base line NYHA functional class.  
 
Missing data in the secondary outcomes will be imputed in an analogous fashion to the primary 
outcome including sensitivity analy ses to define the range of uncertainty imposed by missing data 
(worst case scenario and complete case analysis). The worst case scenario is di fferent by variable. BNP 
and right ventricular basal diameter will be set to the highest value in the observed pop ulation. TAPSE 
will be assumed to be zero, emPHasis -10 score will be assumed to be 50, NYHA functional class  will be 
assumed to be IV, and a participant will be assumed to have escalated PAH specific care.  
 
 
9.4.4  SAFETY ANALYSES  
 
All reported (S)AEs will be co ded using MedDRA and grouped by body system. (S)AEs will be tabulated 
by treatment group using standard coding terms. Incidence of AEs by treatment arm will be tabulated by 
seriousness, severity, and relationship to study drug. If an AE is reported more th an once for a given 
subject, the greatest severity and the worst -case relationship will be presented in tables. The number of 
SAEs and AEs will be summarized for each treatment group as follows: (i) The proportion of subjects 
with at least one (S)AE, (ii) The average number of (S)AEs per subject, and (iii) The rate of (S)AEs per 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   26 subject week of follow -up. Histograms showing the frequency of the number of (S)AEs in each treatment 
group will be included. Rates of (S)AEs by System Organ C lass (SOC) will be pre sented by treatment 
group. Poisson regression modeling will be used to derive ra te ratios and 95% CIs for each SOC. Rate 
ratios will be compared using a two -sided 0.05 level test for Poisson count data.  
 
Safety lab data at each study visit and changes fro m baseline will be summarized by treatment group. In 
addition, clinical laboratory summaries will be presented by treatment group including: (i) incidence of 
significant abnormalities by visit; (ii) tables summarizing the frequencies of subjects below, wit hin, and 
above the normal reference ranges at baseline and end of study; and (iii) tables displaying baseline to 
end of study shifts in each laboratory value (shifts between  below, within or above normal range).  
 
Although drug discontinuation is anticipat ed to be infrequent, the proportion of subjects permanently 
discontinuing study drug will be tabulated by treatment group. Drug discontinuation events will be 
categorized as: (1) Permanently discontinued study drug and (2) Permanently discontinued study dr ug 
and withdrew from study. The reason for permanent drug discontinuation will be summarized. The 
number of hospitalization events and proportion of subjects hospitalized from baseline to study 
termination will be summarized and compared by treatment group . Poisson regression modeling will be 
used to derive rate ratios and 95% CIs to compare hospitalization rates between treatment groups.  
 
9.4.5  DEMOGRAPHIC AND BASELINE DESCRIPTIVE STATISTICS  
Treatment groups will be described and compared with respect to baseline demographic and clinical 
characteristics such as age, gender, race, ethnicity, height, weight, body mass index, use of concomitant 
medications, and markers of pulmonary hypertension dis ease severity (e.g., right ventricular structure 
and function, BNP, 6-minute walk distance, New York Heart Association (NYHA) functional class). 
Continuous measures will be analyzed using t -tests and categorical variables will be analyzed using chi -
square, Fisher9s exact, or Cochran -Mantel -Haenszel tests.  
 
9.4.6  DSMB REVIEW OF ONGOING DATA   
 
Reports to the DSMB will focus on trial integrity (recruitm ent, protocol deviations/violations, 
completeness of follow -up and adherence) and safety. Comprehensive safety interim reports will be 
provided semi -annually to the DSMB. Comprehensive, safety repo rts will include detailed summaries of 
all SAEs, AEs, laboratory parameter listings, drug discontinuations and withdrawals as well as other 
pertinent safety data. The DSMB will recommend continuation or discontinuation of the study based on 
these interim r eviews. Because of the length, size, and scope of the proposed s tudy interim analyses for 
efficacy or futility will not be performed.   
  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   27 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFO RMED CONSENT PROCESS  
 
10.1.1.1  CONSENT  AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS  
 
Consent forms describing in detail the study intervention , study procedures, and risks are given  to the 
participant  and written documentation of informed consent is r equired prior to administering study 
intervention .   
 
All participants will be given a list of H2 receptor antag onists to avoid during the trial.  
 
10.1.1.2  CONSENT PROCEDURES AND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual9s agreeing to participate in the 
study and continues throughout the individual9s study participation.  Consent forms will be Institutional 
Review Board ( IRB)-approved and the participant  will be asked to read and review the document.  A 
study team  member  will explain the research study to the participant  and answer any questions that 
may arise. A verbal explanation will be provided in terms suited to the  participant9s comprehension of 
the purposes, procedures, and potential risks of the study and o f their rights as research participants.  
Participants will have the opportunity to carefully review the wr itten consent form and ask questions 
prior to signing.  The participant s will be given adequate opportunity to consider all o ptions by allowing 
subjects to take the consent form home and to contact the study team at a later time if they would like 
to participate. The participant  will sign the informed consent document prior to any p rocedures being 
done specifically for the study.  Participant s must be in formed that participation is voluntary and that 
they may withdraw from the study at any time, without prejudice.  A copy of the informed consent 
document will be given to the participant s for their records. The informed consent process will be 
conducted and  documented in the source document (including the date), and the form signed, before 
the participan t undergoes any study -specific procedures.  Study -specific procedures (like right heart 
catheterization) may be scheduled but not performed before consent is obtained. Many of the study 
endpoints including the six -minute walk distance, BNP, NYHA functional class, and e chocardiogram are 
also part of routine clinical care. As such clinically obtained testing within the specified time window 
may be used as part of  the baseline research assessment. Because these tests are not <study -specific= it 
is not considered a violation if they are obtained before consent is ob tained. The rights and welfare of 
the participant s will be protected by emphasizing to them that the q uality of their medical care will not 
be affected if they decline to participate in this study.  
 
10.1.2  STUDY DISCONTINUATION AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to study p articipants, investigator, funding agency, and 
regulatory authorities.  If the study is prematurely terminated or suspended, the Principal Investigator 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   28 (PI) will promptly inform study participants, the Institutional Review Board (IR B), and sponsor and will  
provide the reason(s) for the termination or suspension.  Study participants will be contacted, as 
applicable, and be informed of changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
" Determination of unexpected, significant, or unacceptable  risk to participants 
" Demonstration of efficacy that would warrant stopping    
" Insufficient compliance to protocol requirements 
" Data that are not sufficiently complete and/or evaluable 
 
Study may res ume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the sponsor, IRB and/or Food and Drug Administration (FDA).  
 
10.1.3  CONFIDENTIALITY  AND PRIVACY   
 
Participant  confidentiality  and privacy is strictly held in trust by the participating investigators, their 
staff, and the sponsor(s) and their intervention s. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relatin g to participan ts. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor.  
 
All research activities will be conducted in as private a s etting as possible.  
 
Authorized representatives of the sponso r, representative s of the Institutional Review Board (I RB), and 
the U.S. Food and Drug Administration (FDA)  may inspect all documents and records required to be 
maintained by the investigator, including but not li mited to, medical records (office, clinic, or hospita l) 
and pharmacy records for the participant s in this study. The clinical stud y site will permit access to such 
records.  
 
The study participant9s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the reviewing  IRB, Institutional policies, or sponsor requirements . 
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting , will 
be transmitted to and stored at Axio Research . This will not include the participant9s contact or 
identifying information. Rather, individual participants and their rese arch data will be identified by a 
unique study identification number. The study data entry and study management systems used by Axio  
Research staff will be secured and password protected. At the end of the study, all study databases will 
be de -identified and archived at  Axio Research.  
 
Certificate of Confidentiality  
 
To further protect the privacy of study participant s, a Certificate of Confidentiality will be issued by  the 
National Institutes of Health (NIH ).  This certificate protects identifiable research information from 
forced disclosure. It allows the investigato r and others who have access to research records to refuse to 
disclose identifying information on research participation in any civil, criminal, administrative, legisl ative, 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   29 or other proceeding, whether at the federal, state, or local level. By protecting researchers and 
institutions from being compelled to disclose information that would ide ntify research participant s, 
Certificates of Confidentiality help achieve the research objectives and promote participation in studies 
by helping assure confidenti ality  and privacy to participants.  
 
10.1.4  FUTURE USE OF STORED SPECIMENS  AND DATA   
 
Data collected for this study will be analyzed and stored at Axio Research . After the study is completed, 
the de -identified, archived data will be transmitted to and stored at the University of Washington, for 
use by other researchers including those outside of the study. Permission to transmit data to the 
National Institute of Health (NIH) data banks  will be included in the informed consent.  
 
With the participant9s approval and as ap proved by local Institutional Review Boards ( IRBs ), de-
identified biological samples will be stored at the University of Washington  with the same goal as the 
sharing of data with the NIH data banks. A transcript wide analysis of RNA samples  may be performe d. 
These samples could be used for future studies on any topic related to pulmonary vascular disease or 
right heart failure . The NIH will be provided with a code -link that will allow linking the biological 
specimens with the phenotypic data from each participant, maintaining the blind ing of the identity of 
the participant.  
 
During the conduct of the study, an individual participant  can choose to withdraw consent to have 
biological specimens stored for future research. However, withdrawal of consent with regard to 
biosample storage may  not be possible after the study is completed  and data has been submitted to the 
NIH data banks .  
 
When the study is  completed , access to study data and/or samples will be provided through the 
University of Washington.  
 
10.1.5  KEY ROLES AND STUDY GOVERNANCE  
 
Principal Investigator  
Peter Leary, MD, PhD  
University of Washington  
1959 NE Pacific St. 
Seattle, WA 98195  
(206) 685 -2484  
learyp@uw.edu  
 
 
10.1.6  SAFETY OVERSIGHT  
 
Primary safety oversight will be performed by the Principal Investi gator and Study Co -Investigators. 
Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) composed of 
individuals with the appropriate expertise, including  a pulmonary hypertension specialist, a statistician, 
ethics specialist, cardiovascular specialist, and clini cal trials specialist.  Members of the DSMB should be 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   30 independent from the study conduct and free of conflict of intere st, or measures should be in place to 
minimize perceived conflict of interest.  The DSMB will meet at least semiannually to  assess safety and 
efficacy data on each arm of the study. The DMSB will operat e under the rules of an approved charter 
that will be written and reviewed at the o rganizational meeting of the DSMB. At this time, each data 
element that the DSMB needs to assess will be clearly defined. Th e DSMB will provide its input to 
National Institutes of Health  staff. All changes to the protocol or consent will be submitted to th e NHLBI 
and DSMB for review prior to submission to the IRB or execution in the study.  
 
10.1.7  CLINICAL MONITORING  
 
Not applicable.  
 
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
 
The sole clinical site  will perform internal quality management of study condu ct, data and biological 
specimen  collection, documentation and completion.   
 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be r un on the database will be generated. Any missing data or data anomalies will be 
communicated to the site  for clarification/resolution.  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of auditing  and inspection by local and regulatory author ities.  
 
 
10.1.9  DATA  HANDLING  AND  RECORD  KEEPING   
 
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the super vision of the site 
investigator . The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported . 
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation 
of data.   
 
Hardc opies of the study visit worksheets  will be provided for use as source document  worksheets for 
recording data for each participant  enrolled in the study.  Data re cord ed in the electronic case report 
form ( eCRF ) derived from source documents should be consistent with the data recorded on the source 
documents .  
 
Clinical data (including adverse ev ents ( AEs), concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into the International Business Machines (IBM) Clinical 
Development database system provided by  Axio Research . The data system includes p assword 
protection and internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate. Clinical data will be entered dir ectly from the source 
documents.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   31  
 
10.1.9.2  STUDY RECORDS RETENTION  
 
Study docume nts should be retained for a minimum of 6 years after study closure.  
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clini cal trial protocol  or International Conference on 
Harmonization Good Clinical Practice (ICH GCP) . The noncompliance may be either on the part of the 
participant , the investigator, or the study site staff. As a result of deviations, corrective actions are to be 
developed by the site and implemented promptly.  
 
These practices are consistent with ICH GCP:  
" 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
" 5.1 Quality Assurance and Quality Control, section 5.1.1  
" 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
It is the responsibility of the site investigator to use continuous vigilance t o identify and report 
deviations.  All deviations must be addressed in study source documents  and entered into the IBM 
Clinical Development system .  Protocol deviations must be sent to the reviewing  Institutional Review 
Board (IRB)  per their policies.  The site investigator  is responsible for knowing and adhering to the  
reviewing IRB requirements.  
 
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 
This study will  be conducted in accordance with the following publication and data sharing policies and 
regulations:  
 
National Institutes of Health (NIH ) Public Access Policy , which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH f unds to the digital archive PubMed Central  upon acceptance for 
publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results I nformation Submission rule . As 
such, this trial will be registered at ClinicalTrials.gov , and results information  from this trial will be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer -
reviewed journals.   Data from this study may be requested from other res earchers after the completion 
of the primary endpoint by contacting the University of Washington.   
 
In addition, t his study will comply with the NIH Genomic Data Sharing Policy , which  applies to all NIH -
funded research that generates large- scale human or non -human genomic data, as well as the use of these 
data for subsequent research. Large -scale data include transcriptomic, RNA sequencing  data.  
 
 
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   32 10.1.12  CONFLICT OF INTEREST POLICY  
 
The independence of this study from any actual or perceived influence , such as  by the pharmaceutical 
industry , is critical .  Therefore , any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of t his trial  will be disclosed and managed . Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in th e design and conduct of this trial.  The study 
leadership in conjunction with the National Heart, Lung, and Blood Institute (NHLBI)  has established 
policies and procedures for all study group members to disclose all conflicts of interest and will establish 
a mechanism for the management of all reported  dualities of interest.  
 
  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   33 11 REFERENCES  
 
1. Vachiery JL, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs 
JSR, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W. Pulmonary hypertension due to 
left heart diseases. J Am Coll Cardiol . 2013;62:D100 38.  
2. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J . 2008;32:1371 3
1385.  
3. Smith JS, Gorbett D, Mueller J, Perez R, Daniels CJ. Pu lmonary Hypertension and Idiopathic Pulmonary 
Fibrosis -A Dastardly Duo. Am J Med Sci . 2013;  
4. Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McC arthy K, Golish JA, Stoller JK. Frequency and 
impact of pulmonary hypertension in patients with obstructive sleep  apnea syndrome. Am J 
Cardiol . 2009;104:1300 31306.  
5. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin 
Chest Med . 2013;34:639 3650.  
6. Vonk- Noordegraaf A, Westerhof BE, Westerhof N. The Relation ship Between the Right Ventricle and 
its Load in Pulmonary Hypertension. J Am Coll Cardiol . 2017;69:23 63243.  
7. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg- Maitland M, Archer SL. Long -term Effects of 
Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension. 
Chest . 2010;138:1234 31239.  
8. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Bru ndage BH, Detre KM, Fishman AP, Goldring RM, 
Groves BM, Kernis JT. Survival in patients with primary pulmon ary hypertension. Results from a 
national prospective registry. Ann Intern Med . 1991;115:343 3349.  
9. Benza RL, Miller DP, Barst RJ , Badesch DB, Frost AE, McGoon MD. An evaluation of long -term survival 
from time of diagnosis in pulmonary arterial hypertension from the REVE AL Registry. Chest . 
2012;142:456.  
10. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Fa rber HW, Lindner JR, Math ier MA, McGoon MD, 
Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 E xpert consensus document 
on pulmonary hypertension. J Am Coll Cardiol . 2009;53:1573 31619.  
11. Vonk- Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lume ns J, Naeij e R, Newman J, Oudiz 
RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Rig ht heart adaptation to pulmonary 
arterial hypertension: physiology and pathobiology. J Am Coll Cardiol . 2013;62:D22 333.  
12. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The Right Ventricle Under Pressure: Cellular and 
Molecular Mechanisms of Right -Heart Failure in Pulmonary Hypertension. Chest . 2009;135:794 3
804.  
13. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Ga o Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R. 
Molec ular signature of a right heart failure program in chronic severe pulmonary hypertension. 
Am J Respir Crit Care Med . 2011;45:1239 31247.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   34 14. van Campen JS, de Boer K, van de Veerdonk MC, va n der Bruggen CE, Allaart CP, Raijmakers PG, 
Heymans MW, Marcus JT,  Harms HJ, Handoko ML, de Man FS, Vonk -Noordegraaf A, Bogaard HJ. 
Bisoprolol in idiopathic pulmonary arterial hypertension: an e xplorative study. Eur Respir J . 
2016;48:787 3796.  
15. Bristow MR, Ginsburg R, Harrison DC. Histamine and the  human heart: the ot her receptor system. 
Am J Cardiol . 1982;49:249 3251.  
16. Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayas hi M, Matsuyama K, Kawakami N, Sakuma I, 
Gando S, Fukui H, Hattori Y, Levi R. Histamine H1 and H2 receptor gene and protein levels are 
differentially  expressed in the hearts of rodents and humans. J Pharmacol Exp Ther . 
2004;309:795.  
17. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johns on GA, Ishimoto BM, Sageman WS, 
Daniels JR. Anthracycline- associated cardiac and renal damage in rabbits. Evidenc e for mediation 
by vasoactive substances. Lab Invest . 1981;45:157 3168.  
18. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, S ageman WS, Billingham ME. Mediation of 
subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiova sc 
Pharmacol . 1983;5:913 3919.  
19. Takahama H, Asanuma H, Sanada S, Fujita M, Sasaki H , Wakeno M, Kim J, Asakura M, Takashima S, 
Minamino T, Komamura K, Sugimachi M, Kitakaze M. A histamin e H2 receptor blocker 
ameliorates development of heart failure in do gs independently of ³- adrenergic receptor 
blockade. Basic Res Cardiol . 2010;105:787 3794.  
20. Zeng Z, Shen L, Li X, Luo T, Wei X, Zhang J, Cao S , Huang X, Fukushima Y, Bin J, Kitakaze M, Xu D, Liao 
Y. Disruption of histamine H2 receptor slows heart failure  progression through reducing 
myocardial apoptosis and fibrosis. Clin Sci . 2014;127:448.  
21. Luo T, Chen B, Zhao Z, He N, Zeng Z, Wu B, Fukus hima Y, Dai M, Huang Q, Xu D, Bin J, Kitakaze M, 
Liao Y. Histamine H2 receptor activation exacerbates myocardial i schemia/reperfusion injury by 
disturbing mitochondrial and endothelial function. Basic Res Cardiol . 2013;108:342.  
22. Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heck bert SR, Kawut SM, Krieger EV, Lima JA, Masri 
CS, Ralph DD, Shea S, Weiss NS, Kronmal R A. Histamine H2 Receptor Antagonists, Left Ventricular 
Morphology, and Heart Failure Risk: The MESA Study. J Am Coll Cardiol . 2016;67:1544 31552.  
23. Kim J, Ogai A, Nakatani S, Hashimura K, Kanzaki H, Ko mamura K, Asakura M, Asanuma H, Kitamura S, 
Tomoike H , Kitakaze M. Impact of blockade of histamine H2 receptors on chronic heart failure 
revealed by retrospective and prospective randomized studies. J Am Coll Cardiol . 2006;48:1378 3
1384.  
24. Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jone s KL, Kao DP, Ka wut SM, Krieger EV, Lima JA, 
Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. H istamine H2 receptor polymorphisms, 
myocardial transcripts and heart failure: The Multi -Ethnic Study of Atherosclerosis and Beta -
blocker Effect on Remodeling and Gene Expre ssion Trial, Under Review (Aug 2017).  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   35 25. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD , Farber HW, Frost AE, Liou TG, Turner M, 
Feldkircher K, Miller DP, Elliott CG. Delay in recognition of pulmonary arterial  hypertension: 
factors identified from the REVEAL Registry. Chest . 2011;140:19 326.  
26. Leary PJ, Barr RG, Bluemke DA, Bristow MR, Kronmal RA, Lima JA, Ralph DD, Ventetuolo CE, Kawut 
SM. H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study. 
Ann Am Thorac Soc . 2014;11:1386.  
27. Leary PJ, Hess E, Barón AE, Branch KR, Bristow MR , Choudhary G, Grunwald GK, Hough CL, Kronmal 
RA, Mahr C, Maron BA, Ralph DD, Ryan JJ, Tedford RJ,  Weiss NS, Zamanian RT, Lahm T. 
Association between Histamine H2 -receptor antagonist use and mortality among veterans with 
pulmonary hypertension: Insights from the VA -CART Program, Under Review (Sep 2017)  
28. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagno sing the decline in pharmaceutical R&D 
efficiency. Nat Rev Drug Discov . 2012;11:191 3200.  
29. Ishida J, Konishi M, Ebner N, Springer J. Repurposing of approved cardiovascular drugs. J Transl Med . 
2016;14:269.  
30. Nosengo N. Can you teach old drugs new tricks? Nature . 2016;534:314 3316.  
31. Gu S, Hu H, Dong H. Systematic Review of the Econom ic Burd en of Pulmonary Arterial Hypertension. 
Pharmacoeconomics . 2016;34:533 3550.  
32. Noel ZR, Kido K, Macaulay TE. Selexipag for the treatm ent of pulmonary arterial hypertension. Am J 
Health Syst Pharm . 2017;  
33. Strange G, Playford D, Stewart S, Deague JA, Ne lson H, Kent A, Gabbay E. Pulmonary hypertension: 
prevalence and mortality in the Armadale echocardiography cohort. Heart . 2012;98:1805 31811.  
34. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ,  Fox K, Mourad JJ, Boersma E. Angiotensin-
converting enzyme inhibitors reduce mortality in hypertension: a meta -analysis of randomized 
clinical trials of renin -angiotensin -aldosterone system inhibitors involving 158,998 patients. Eur 
Heart J . 2012;33:2088 32097.  
35. Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined 
end points in pulmonary arterial hypertension. Proc Am Thorac Soc . 2008;5:622.  
36. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical 
correlates and prognostic si gnificance of six- minute walk test in patients with primary pulmonary 
hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med . 
2000;161:487 3492.  
37. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mat hier MA, Mehta S, Pal azzini M, Park MH, 
Tapson VF, Sitbon O. Treatment goals of pulmonary hypertension. J Am Coll Cardiol . 
2013;62:D73 381.  
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   36 38. Yorke J, Corris P, Gaine S, Gibbs JSR, Kiely DG, Harr ies C, Pollock V, Armstrong I. emPHasis- 10: 
development of a health -related qual ity of life measure in pulmonary hypertension. Eur Respir J . 
2014;43:1106 31113.  
39. Probstfield JL, Frye RL. Strategies for recruitment a nd retention of participants in clinical trials. J Am 
Med Assoc . 2011;306:1798 31799.  
40. Probstfield JL, Russell ML, Insul W, Yusuf S. Dropouts  from a clinical trial, their recovery and 
characterization. In: Shumaker SA, Schron EB, Ockene JK, editors. The Handbook of Health 
Behavior Change. 2015. p. 13 25. 
41. Probstfield JL, Russell ML, Henske JC, Reardon RJ, I nsull W. S uccessful program for recovery of 
dropouts to a clinical trial. Am J Med . 1986;80:777 3784.  
42. Lovato LC, Hill K, Hertert S, Hunninghake DB, Probst field JL. Recruitment for controlled clinical trials: 
literature summary and annotated bibliography. Control  Clin Trials . 1997;18:328 3352.  
43. Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR,  Lovato LC, Margolis KL, Rosenberg Y, Sperl- Hillen 
JM, Vargo L, Williamson JD, Probstfield JL, ACCORD Study Group. Recruitment strategies in the 
Action to Control Cardi ovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol . 2007;99:68i 379i.  
44. Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H,  Egan D, Farber M, Payne G, Probstfield J, Ward 
H, ALLHAT Research Group. Participant recruitment in the Antihyper tensive and  Lipid -Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials . 2001;22:674 3686.  
45. Brooks D, Solway S, Gibbons WJ. ATS statement on six -minute walk test. Am J Respir Crit Care Med . 
2003;167:1287 31287.  
46. ATS Committee on Proficiency Standards. ATS statemen t: guidelines for the six- minute walk test. Am 
J Respir Crit Care Med. 2002;166:111 3117.  
47. Dutta T, Aronow WS. Echocardiographic evaluation of t he right ventricle: Clinical implications. Clin 
Cardi ol. 2017;221:1132.  
48. Gilbert C, Brown MCJ, Cappelleri JC, Carlsson M, McKenna SP. Estimatin g a minimally important    
difference in PAH following treatment with sildenafil. Chest . 2009;135:137 3142.  
 
49. Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6 -minute walk test 
for patients with PAH. Am J Respir Crit Care Med . 2012;186:428 3433.  
 
50. Gray MP, Aldrighetti R, Fagan KA. Participant expectations in pulmona ry hypertension -related 
research studies. Pulm Circ . 2015;5:376 3381.  
  
51. Chakinala MM, Duncan M, Wirth J. Managing the Patient with Pulmonary Hypertension: Specialty 
Care Centers, Coo rdinated Care, and Patient Support. Cardiol Clin . 2016;34:489 3500.  
52. Galiè N, et al. 2015 ESC/ERS Guidelines for the diagnosis  and treatment of pulmonary hypertension: 
The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the  European 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   37 Society of Cardiology (ESC) and the European Respiratory Society (ERS): European Heart Journal. 
2016;37:67 3119.  
53. McLaughlin VV, et al. ACCF/AHA 2009 Expert consensus  document on pulmonary hypertension. J Am 
Coll Cardiol . 2009;53:1573 31619.  
54. McLaughlin VV, et al. Treatment goals of pulmonary hyp ertension. J Am Coll Cardiol . 2013;62:D73 
81.  
55. Gray MP, Aldrighetti R, Fagan KA. Participant expectations in pu lmonary hypertension -related  
         research studies.  Pulm Circ . 2015;5:376 3381.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   38 12 APPENDIX  1: EMPHASIS -10 QUESTIONNAIRE  
 
 
 

REHAB -PH PROTOCOL  Version 1.8 
 20 Jan 2023  
 
CONFIDENTIAL   39 13 APPENDIX  2: FUNCTIONAL CLASS DECISION AID  
 
Functional Class Decision Aid  
Does the patient have symptoms most likely related to pulmo nary hypertension:  
 1. At rest?  yes        no        n/a        
FC IV  2. When getting up or dressing?  yes        no        n/a        
 3. When washing, brushing teeth or having a shower?  yes        no        n/a        
 4. When walking around in the house?  yes        no        n/a        
 5. When walking on level ground at slow speed?  yes        no        n/a        
 
 6. When climbing up to 2 flights of stairs  
at reduced (slow) speed?  yes        no        n/a        
FC III  7. When walking on level ground  
at normal (pedestrian) speed?  yes        no        n/a        
 
 8. When climbing 2 or more flights of stairs  
at normal speed?  yes        no        n/a        
FC II  9. When walking uphill?  yes        no        n/a        
 
 10. When performing vigorous physical activity?  yes        no        n/a        FC I 
 
Investigator Determined    Functional class for this patient:  WHO FC    
 